Vilazodone is the active medicine in VIIBRYD oral tablets, labeled to treat major depressive disorder in adults. The selected label describes two serotonin-related actions, but does not establish that those actions produce extra benefits. Its side effects, serious warnings, interactions, and evidence gaps matter when interpreting information about this product.

A medicine's scientific description can sound more certain than the evidence actually is. With vilazodone, understanding that distinction helps separate what the label reports from what it cannot predict about you. This guide focuses on one identified VIIBRYD labeling record, not every antidepressant or every version of vilazodone. It explains the adult indication, gastrointestinal and sleep-related reactions, sexual-function concerns, and several distinct interaction pathways. It also covers important limits in the available evidence. It does not provide dosing, switching, or stopping instructions, and it does not establish whether this medicine fits your treatment needs.

Which vilazodone product and approved use does this guide cover?

This guide covers VIIBRYD, identified as vilazodone hydrochloride tablets for oral use, with an adult major depressive disorder indication. MVBH's explanations of medicine information and Medication Guides and serious risks provide context for understanding the product information discussed here.

Section 1 of the selected FDA label identifies major depressive disorder, or MDD, in adults as the approved use. This record does not establish approved indications for anxiety disorders, obsessive-compulsive disorder, bipolar depression, or insomnia.

That distinction matters when several concerns occur together. Having depression and trouble sleeping does not make insomnia a separate approved indication. Equally, the absence of another indication does not prove that a clinician could never prescribe the medicine for another purpose. The narrower point is what this particular labeling record establishes, not a personal recommendation or a rule covering every prescribing circumstance.

What do vilazodone's two serotonin actions actually establish?

The label describes serotonin reuptake inhibition and partial agonist activity at 5-HT1A receptors, while leaving important parts of the antidepressant mechanism uncertain. The distinction between technical wording and patient-facing explanation is discussed in MVBH's medicine-information guide.

Reuptake is the reabsorption of a chemical messenger after its release. Inhibiting serotonin reuptake changes serotonin signaling. Partial agonist activity means a medicine activates a receptor without producing its full possible response. These terms describe two aspects of vilazodone's activity, not two separately established treatment benefits.

Section 12.1 of the selected FDA label states that the overall mechanism in MDD is not fully understood. It also says the effect of the receptor action on serotonin transmission, and its contribution to antidepressant benefit, are unknown.

Two actions therefore do not establish faster relief, fewer sexual side effects, or superiority to another antidepressant. They also do not show that an individual's depression resulted from a serotonin deficiency. A description of drug activity cannot, by itself, explain why a particular person developed depression.

Which side effects does the VIIBRYD label report?

Diarrhea, nausea, vomiting, and insomnia are the label's most commonly observed adverse reactions under its stated trial definition. MVBH's resources on serious-risk information and professional medicine information help distinguish a reported possibility from a prediction about your experience.

In the placebo-controlled MDD studies summarized in section 6.1, these reactions occurred in at least 5% of VIIBRYD-treated participants and at least twice the placebo rate. That definition explains why they receive emphasis. It does not mean they are the only possible reactions or that everyone experiences them. The selected FDA label also includes a separate sexual-dysfunction warning.

  • Gastrointestinal effects: Diarrhea, nausea, and vomiting are separate reported reactions. The findings do not establish how long an individual's symptoms will last.
  • Sleep effects: Insomnia, meaning difficulty sleeping, appears among the most commonly observed reactions. A new sleep problem still needs interpretation in the person's wider health context.
  • Sexual effects: The label recognizes reduced desire, delayed or absent orgasm, delayed or failed ejaculation, and erectile difficulties. Vilazodone should not be described as free of sexual side effects.

The sexual-function warning specifically notes that symptoms may have other causes, including the underlying psychiatric condition. Timing and prior function matter when evaluating a change. Recognizing a possible medicine effect is different from proving that the medicine caused one person's symptom.

Postmarketing reports are another kind of information. Section 6.2 explains that voluntary reports come from a population of uncertain size, so frequency and causation cannot always be established. Trial rates also cannot be directly compared with another medicine's trial rates. Neither source supports ranking vilazodone against other antidepressants here.

Which serious warnings are separate from common side effects?

The label's serious warnings address potentially severe outcomes, not simply the reactions most often reported in trials. MVBH's explanations of Medication Guide risk language and full prescribing information provide context without predicting anyone's individual risk.

The boxed warning has direct adult relevance. Pooled short-term antidepressant studies found increased suicidal thoughts and behaviors among young adults ages 18 to 24 compared with placebo. These were broader antidepressant analyses, not a vilazodone-only estimate. The label calls for monitoring all treated patients for worsening depression or emerging suicidal thoughts, particularly early in treatment. Monitoring everyone does not mean that the studies found equal risk at every age. See sections 5.1 and 17 of the selected FDA label.

Serotonin syndrome is a potentially life-threatening reaction that can occur with vilazodone alone or with other serotonergic medicines. It can involve changes in mental state, body temperature, heartbeat, and muscle control. Nausea or diarrhea alone does not diagnose it, even though gastrointestinal symptoms can be part of the syndrome.

Other warnings include increased bleeding, activation of mania or hypomania, seizures, and low blood sodium. Severe low sodium can cause confusion, seizures, or loss of consciousness. The eye warning concerns angle-closure glaucoma in people with particular anatomical susceptibility; eye pain or vision changes require prompt medical attention. The label also recognizes discontinuation-related symptoms, especially after abrupt cessation. These warnings appear in sections 5.2 through 5.8 of the selected FDA label.

Suspected serious medicine reactions need urgent medical attention, not a routine outpatient inquiry. Call 911 for immediate danger or life-threatening symptoms. Call or text 988 for suicidal or emotional crisis support; 988 is not treatment for a drug reaction. NIMH provides this crisis and emergency guidance. MVBH is not an emergency service.

Why do other medicines matter to this particular label?

Other medicines can change vilazodone exposure, add to certain risks, or themselves be affected by vilazodone. These are different interaction pathways. MVBH's guides to professional medicine information and serious-risk context explain why an isolated warning cannot settle a medication decision.

CYP3A4 is an enzyme involved in medicine metabolism. The label reports that strong CYP3A4 inhibitors increased vilazodone exposure, while strong inducers decreased it. Exposure describes how much medicine is present in the body over time. This is different from an interaction that adds bleeding risk without necessarily changing vilazodone exposure.

There is also an interaction in the other direction: VIIBRYD increased digoxin concentrations. Digoxin has a narrow therapeutic index, meaning the range between useful and harmful exposure is relatively small. These findings appear in section 7.1 of the selected FDA label.

Different kinds of interaction information in the selected VIIBRYD label
Label categoryWhat the label describesWhat it does not decide
Strong CYP3A4 inhibitors and inducersInhibitors increased vilazodone exposure; inducers decreased it.A reader-selected prescription adjustment.
Other serotonergic medicines and monoamine oxidase inhibitors (MAOIs)Increased serotonin-syndrome risk, with specified MAOI contraindications.Permission to combine medicines.
Antiplatelet agents and anticoagulantsAdditional bleeding risk with combined use.An instruction to stop another prescribed medicine.
DigoxinIncreased digoxin concentrations with VIIBRYD.An individual monitoring or management plan.

The interaction information is not limited to psychiatric treatment. The MAOI contraindication includes the antibiotic linezolid and intravenous methylene blue. The bleeding warning includes aspirin and nonsteroidal anti-inflammatory drugs as well as prescription blood thinners. This article does not reproduce timing intervals or adjustment instructions; the product-specific interaction decision requires professional interpretation.

Where does the label leave important questions unanswered?

The label describes different evidence gaps for older adults, pregnancy, lactation, seizure disorders, and bipolar disorder. These gaps are not interchangeable. MVBH's medicine-information guide provides context for the scope of professional labeling, while the details below remain specific to VIIBRYD.

Sections 8.1, 8.2, and 8.5, together with the seizure and mania warnings in the selected FDA label, distinguish several limitations:

  • Older adults: Clinical studies included too few participants age 65 and older to determine whether their response differs from younger adults. Similar drug-handling findings in a separate study do not resolve that response question.
  • Pregnancy: There are no adequate, well-controlled VIIBRYD studies in pregnant women. The label discusses possible newborn complications after late-pregnancy exposure and bleeding near delivery, alongside risks from untreated depression.
  • Lactation: Human data are unavailable on vilazodone in milk, effects on a breastfed infant, or milk production. Findings in rat milk do not answer those human questions.
  • Seizure disorders: VIIBRYD has not been systematically evaluated in this population, and people with a seizure history were excluded from clinical studies.
  • Bipolar disorder: People with bipolar disorder were excluded from controlled trials. Those trials therefore do not establish benefit for bipolar depression, and the label separately warns about mania or hypomania activation.

Limited or unavailable evidence is not proof of either safety or harm. It defines what remains uncertain. Likewise, the supplied extract does not include the full Clinical Studies section, so this guide does not claim a response timeline, remission rate, or long-term benefit.

Product facts and treatment choices serve different purposes. NIMH explains that treatment planning should reflect individual needs and medical circumstances with professional guidance. Psychotherapy may be used alongside medication or as another treatment option. That general principle does not establish a vilazodone-specific effect or make this article a personal treatment plan.

Source record: This guide is bound to VIIBRYD application NDA022567, set_id 4c55ccfb-c4cf-11df-851a-0800200c9a66, and spl_id 7502bf82-6281-4d90-8471-1450580c4f3c. The supplied effective_time is 20231001; the Medication Guide separately prints revision 4/2024. These are source-record details, not article publication dates or proof that this is the latest available labeling.

Written by Tim Francis, SUD Content Specialist. This article is educational and does not replace professional medical advice, diagnosis, or treatment.

Frequently asked questions

Does vilazodone's serotonin activity mean it treats anxiety disorders?

No. A pharmacological action does not establish an approved indication. The selected VIIBRYD label identifies adult major depressive disorder, not anxiety disorders, as its indication. Anxiety occurring alongside depression does not change that labeling distinction. Whether another prescribing purpose is appropriate is a separate clinical decision that this article cannot make.

Is vilazodone free of sexual side effects?

No. The selected label includes a sexual-dysfunction warning covering desire, orgasm, ejaculation, and erectile function. It also recognizes that sexual symptoms can have other causes, including the psychiatric condition being treated. The warning supports taking a change seriously without assuming that medicine exposure proves the cause in an individual.

Does diarrhea while taking VIIBRYD mean serotonin syndrome?

Diarrhea alone does not establish serotonin syndrome. It is also among the commonly reported adverse reactions in the selected label. Serotonin syndrome can involve changes in mental state, temperature, heartbeat, and muscle control. Suspected serious reactions require urgent medical attention rather than diagnosis from an article. Call 911 for life-threatening symptoms.

Why does the label discuss digoxin?

The selected VIIBRYD label reports that combined use increased digoxin concentrations. This illustrates that an interaction can affect the other medicine, not just vilazodone. Digoxin has a narrow therapeutic index, making exposure changes important. The finding is not a self-management instruction; individual interpretation and any management belong with qualified professionals.

Does missing human-milk information prove vilazodone is unsafe?

No. Missing information is not proof of harm, but it is not reassurance of safety either. The selected label lacks human data on milk presence, infant effects, and milk production. It describes weighing breastfeeding benefits, clinical treatment needs, and potential effects from the medicine or underlying condition.

Vilazodone: Related Guides

For more context, explore the full article library, Asenapine: Labeled Uses and Safety for Adults | PHP/IOP MA, Citalopram: Labeled Uses and Safety for Adults | PHP/IOP MA.